The Impact of the Tumor Microenvironment on Immune Checkpoint Inhibitor Resistance in Prostate Cancer: Mechanistic Insights and Therapeutic Strategies.
While immune checkpoint inhibitors (ICIs) have revolutionized the treatment landscape for melanoma and lung cancer, their efficacy in prostate cancer (PCa) remains limited. This therapeutic resistance is linked in part to the "cold" immunophenotype of PCa, which is orchestrated by a highly immunosuppressive tumor micro...